Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Characteristics and treatment details of patients with esophageal carcinoma included in this study (N = 20)

From: Dosimetric rationale and preliminary experience in proton plus carbon-ion radiotherapy for esophageal carcinoma: a retrospective analysis

Characteristics

Data

Sex, n (%)

 

 Male/ Female

15 (75) / 5 (25)

Age, years, median (range)

70 (54–85)

Tumor location, n (%)

 

 Cervical/ Upper/ Middle/ Lower thoracic

2 (10) / 8 (40) / 6 (30) / 4 (20)

SUVmax

 

 mean

12.1

 median, range

10.7 (3.6–31.6)

T classification, n (%)

 

 T2/ T3/ T4

4 (20) / 15 (75) / 1 (5)

N classification, n (%)

 

 N0 / N1/ N2

5 (25) / 10 (50) / 5 (25)

Stage, n (%)

 

 II/ III/ IV

6 (30) / 8 (40) / 6 (30)

Concurrent chemotherapy

 

 Yes/ No

9 (45) / 11 (55)

Dose of proton radiotherapy

 

 median, range

50 Gy (44–56) / 25 fractions (22–28)

Dose of carbon ion radiotherapy

 

 median, range

21 Gy (15–23.1) / 7 fractions (5–7)

  1. Doses are presented as the RBE (relative biological effectiveness)-weighted dose
  2. Abbreviations: SUVmax, the maximum standard uptake value
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us